Myriad Genetics Cut to Underweight as Piper Questions Path to Profit
Piper Sandler double-downgraded MYGN, saying the current model cannot grow or cut its way to profit.
/ 2 items
Piper Sandler double-downgraded MYGN, saying the current model cannot grow or cut its way to profit.
Myriad Genetics' MyChoice CDx gains FDA approval as the only CDx to identify HRD-positive patients for Zejula maintenance in advanced ovarian cancer, boosting precision therapy.